Published online 22 June 2009
Haematologica, Vol 94, Issue 8, 1177-1179 doi:10.3324/haematol.2009.008359
Copyright © 2009 by Ferrata Storti Foundation
Hansjoerg Schmid1 ,
Bernadette A.S. Jaeger2 ,
Judith Lohse2 ,
Meinolf Suttorp2
Also in children, rapid control of Philadelphia+ CML has been achieved by imatinib.6 However, in adults side-effects affecting bone metabolism were described in 2006 hypothesizing that unspecific inhibition of tyrosine kinases (c-KIT, PDGF-
, -β, c-FMS) which are either expressed by osteoblasts and osteoclasts may impair bone remodeling.7 This mechanism was demonstrated to be active in adult mice.8 Further reports providing evidence that imatinib treatment does affect bone metabolism followed rapidly.9,10 Also in a model of juvenile mice, long-term imatinib treatment had an anti-resorptive effect on osteoclasts and impaired the length of tubular bone. These effects on the growing skeleton were more pronounced in prepubertal animals.11 
HS and BAS J contributed equally to this work.
Haematologica, Vol 94, Issue 8, 1177-1179 doi:10.3324/haematol.2009.008359
Copyright © 2009 by Ferrata Storti Foundation
Chronic Myeloid Leukemia |
Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib
1 Department of Pediatric Hematology and Oncology, Medical School, Hannover;
2 Division of Pediatric Hematology and Oncology, University Hospital Carl Gustav Carus, Dresden, Germany
Correspondence: Meinolf Suttorp, Pädiatrische Hämatologie und Onkologie, Universitätsklinikum Carl Gustav Carus Fetscherstr. 74 D-01307 Dresden, Germany. Phone: international +49.351.4583522. Fax: international +49.351.4585864. E-mail:meinolf.suttorp{at}uniklinikum-dresden.de
Recently Jonsson et al. reported on increased cortical bone mineralization as a side effect in imatinib treated adult patients with chronic myelogenous leukemia (CML).1 Also for pediatric CML targeted therapy by this tyrosine kinase inhibitor has been replacing stem cell transplantation (SCT) as front-line treatment.2 Thus, although CML is rare in childhood, the number of children treated by imatinib is constantly growing. However, side effects of imatinib on the immature skeleton might differ from adults. We here report on massive growth retardation while on imatinib treatment.
The patient was born as one of triplets at the 34th week of gestation (weight: 2540 g; length: 47 cm). Her further development was uneventful until the age of 5
years when Philadelphia+ CML was diagnosed. Treatment with imatinib (GlivecTM) starting in October 2005 was tolerated without specific side effects. Regular follow-up examinations confirmed ongoing remission and at 40 months on treatment the BCR-ABL rearrangement was undetectable. However, growth retardation had been observed already six months after treatment with imatinib had been initiated. While at diagnosis her body height was equivalent to the 74th percentile it fell to the 9th percentile after three years of treatment (Figure 1). Regular monitoring of bone biochemical markers exhibited increased excretion of urinary Ca, pyridinoline (PYR) and desoxypyridinoline (DPYR), reduced serum N-terminal propeptide of type I collagen (PINP) and increased serum osteocalcin (Table 1). X-ray of the left hand demonstrated skeletal age retardation of 22 months at the age of eight years. Further diagnostics showed partial growth hormone (GH) deficiency (IGF1: 43 ng/mL and 60 ng/mL at the age of seven years and eight years, respectively: normal values: 64–345 ng/mL). No other drugs beside imatinib had been taken by the patient. The two heterozygous triplet siblings showed normal hematologic parameters and their growth followed the 82nd and 55th percentiles, respectively.
 View larger version (14K): [in a new window] [Download PPT slide] |
Figure 1. Decrease in body height under imatinib therapy (percentiles according to Hesse, Jaeger, Vogel et al. 1997).3
|
|
View this table: [in a new window] [Download PPT slide] |
Table 1. Analysis of biochemical markers of bone metabolism. (N) depicts normal values while pathological values are indicated by ( ) if increased, and by ( ) if decreased.
|
, -β, c-FMS) which are either expressed by osteoblasts and osteoclasts may impair bone remodeling.7 This mechanism was demonstrated to be active in adult mice.8 Further reports providing evidence that imatinib treatment does affect bone metabolism followed rapidly.9,10 Also in a model of juvenile mice, long-term imatinib treatment had an anti-resorptive effect on osteoclasts and impaired the length of tubular bone. These effects on the growing skeleton were more pronounced in prepubertal animals.11 Mariani et al. observed a 9-year old boy who developed impaired growth shortly after the start of imatinib treatment which resolved at the onset of puberty resulting in no deficiency of his prospective final height.12 GH deficiency was excluded in this case but endocrinological abnormality in the form of a reduced inhibin B/FSH ratio was present. However, in contrast to other reports on findings in adults and animal data he exhibited reduced bone mineral density of his lumbar vertebrae as determined by DXA following six years of imatinib treatment.
Skeletal growth impairment is of major concern in pediatric patients. In the girl described here cumulative data of biomarkers of mineral and skeletal homeostasis showed a slight increase in bone turnover as the plasma osteocalcin level was elevated while bone formation was reduced as indicated by lowered plasma PINP. Urinary Ca excretion was increased as were the urinary concentrations of the collagen cross-links PYR and DPYR which are indicative of bone resorption. These alterations may not be attributed to the partial GH deficiency as in children with this disorder urinary concentration of PYR and DPYR is lower than in healthy controls.13 Thus, these data suggest a prevalence of bone resorption over formation by which skeletal growth is affected resulting in the impressive cutting score of the length percentiles noticed. It is noteworthy that the growth of her two triplet siblings was unaffected. Whether catch-up growth at the onset of puberty as reported by Marani et al. will also occur in the girl reported here has to be studied in the future as she is still prepubertal.9 The underlying partial GH-deficiency may represent a major obstacle to this hope. However, without standardized testing random GH measurements may be inconclusive.
As the number of children with CML on long-term imatinib treatment is constantly increasing, so far unobserved and/or unreported side effects of this small molecule inhibitor may play a more important role in the future. As SCT may also result in growth impairment, the choice of the optimal treatment for pediatric CML remains an ongoing challenge.
Footnotes
HS and BAS J contributed equally to this work.
References
 TOP References |
|---|
- Jonsson S, Olsson B, Ohlsson C, Lorentzon M, Mellström D, Wadenvik H. Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia. Haematologica 2008;93:1101-3.
[Free Full Text] - Millot F, Guilhot J, Nelken B, Leblanc T, De Bont E, Bekassy AN, et al. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia 2006;20:187-92.[CrossRef][Web of Science][Medline]
- Hesse V, Jaeger U, Vogel H, Kronmeyer Z, Zeliner K, Bernhardt I, et al. Data on growth of German children from birth up to 18 years. Sozialpaediatrie 1997;19:20-2.
- van der Sluis IM, Hop WC, van Leeuwen JPTM, Pols HA, de Muinck, Keizer-Schrama SM. A cross sectional study on biochemical parameters of bone turnover and vitamin D metabolites in healthy Dutch children and young adults. Horm Res 2002;57:170-9.[CrossRef][Web of Science][Medline]
- Yang L, Drey V. Pediatric reference intervals for bone markers. Clin Biochem 2006;39:561-8.[CrossRef][Web of Science][Medline]
- Suttorp M. Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT. Bone Marrow Transplant 2008;42 Suppl_2: S40-6.[CrossRef][Web of Science][Medline]
- Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006;354:2006-13.
[Abstract/Free Full Text] - O’Sullivan S, Naot D, Callon K, Porteous F, Horne A, Wattie D, et al. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteo-clastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res 2007;22:1679-89.[CrossRef][Web of Science][Medline]
- Osorio S, Noblejas AG, Duran A, Stegmann JL. Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response. Am J Hematol 2007;82:394-5.[CrossRef][Web of Science][Medline]
- Fitter S, Dewar AL, Kostakis P, To LB, Hughes TP, Roberts MM, et al. Long-term imatinib therapy promotes bone formation in CML patients. Blood 2008;111:2538-47.
[Abstract/Free Full Text] - Suttorp M, Boehme J, Vaitl J, Mosch B, Pursche S, Jung R, et al. Side effects on the heart and skeleton of growing mice attributed to chronic imatinib exposure. Blood 2008;112:402[Abstract].
- Mariani S, Giona F, Basciani S, Brama M, Gnessi L. Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty. Lancet 2008;372:111-2.[CrossRef][Web of Science][Medline]
- Fujimoto S, Kubo T, Tanaka H, Miura M, Seino Y. Urinary pyridinoline and desoxy pyridinoline in healthy children and in children with growth hormone deficiency. J Clin Endocrinol Metabol 1995;80:1922-8.[Abstract]
This article has been cited by other articles:
 |
|
 |
|
  K. Vandyke, S. Fitter, A. L. Dewar, T. P. Hughes, and A. C. W. Zannettino Dysregulation of bone remodeling by imatinib mesylate Blood, January 28, 2010; 115(4): 766 - 774. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||